IHS Chemical Week

People & Business :: Companies

Solvay Reports Higher Sales and Profit; Focuses on 'Optimal Reinvestment' Following Disposal of Pharma Unit

1:18 AM MDT | July 29, 2010 | Natasha Alperowicz

Solvay's recurring group operating result (Rebit) from continuing operations, following the sale of its pharmaceuticals business, rose to €183 million ($237.8 million) in the second quarter of this year, compared to €63 million in the same period of 2009. Sales were down 11% to €1.85 billion, following the divestment of the pharma business but up 32% compared with chemicals and plastics in the first quarter of 2009. Chemicals sales were 12% higher at €762 million while plastics revenues rose 50% to €1.1 billion. Second quarter chemicals...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa